KY19334, a small molecule that activates the Wnt/β-catenin pathway via interference of the CXXC5-Dvl interaction, reversed the overall pathogenic features of NASH as Cxxc5−/− mice. Here, CXXC5 is linked to metabolic dysfunction-associated steatohepatitis.